Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

electroCore to Present at Noble Capital Markets’ Fifteenth Annual Investor Conference

January 28, 2019 at 8:00 AM EST

BASKING RIDGE, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced Chief Executive Officer, Frank Amato and Chief Science & Strategy Officer, JP Errico will present at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference in Fort Lauderdale, Florida - on Tuesday, January 29, 2019 at 10:30 a.m. Eastern Standard Time.

Interested parties may access an archived webcast of the presentation on the “Investors” section of the company’s website at:

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The Company’s initial targets are the acute treatment of migraine and episodic cluster headache and the prevention of cluster headache.

For more information, visit  

Hans C Vitzthum
LifeSci Advisors


Alexandra Canale
GCI Health
(617) 921-9353